MAPK3 and breast carcinoma: Antitumor activity of trastuzumab was enhanced when combined with brusatol in HER2-positive breast cancer cells, which was attributed to the inhibition of the Nrf2/HO-1 and HER2-Akt/Erk1/2 signaling cascades [32].